Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 100 WF4.2 | DOI: 10.1530/endoabs.100.WF4.2

SFEEU2024 Society for Endocrinology Clinical Update 2024 Workshop F: Disorders of the parathyroid glands, calcium metabolism and bone (15 abstracts)

Treatment refractory post-surgical hypoparathyroidism requiring recombinant PTH (teriparatide) administration

Izan Idris & Harit Buch


New Cross Hospital, Wolverhampton, United Kingdom


We present a case of a 43 year-old male with permanent post-operative hypoparathyroidism following total thyroidectomy for toxic nodular goitre. His medical history includes Mccune-Albright syndrome and mild right optic atrophy. He had prolonged hospital stay post-surgery due to persistent severe hypocalcaemia with mild hypomagnesemia. Post-surgery, hypocalcaemia was treated with intermittent calcium infusion, oral calcium and D3 supplements and vitamin D analogues of alfacalcidol 4 microgram daily which was switched to calcitriol 2 mg daily due to lack in calcium improvement. He was also commenced on regular oral magnesium replacements. Despite maximal oral and intravenous treatment, normocalcaemia was not achieved hence recombinant PTH of Teriparatide was commenced at 40 mg daily subcutaneously. He was discharged following normocalcaemia and was regularly followed up for calcium monitoring. Hypoparathyroidism and hypocalcaemia is a common postoperative complication after total thyroidectomy. Standard treatment with supplementation of calcium and vitamin D analogues, usually treat this condition. Uncommonly, in some cases including our patient, hypoparathyroidism is refractory to standard treatment and recombinant PTH is required to achieve normocalcaemia.

Article tools

My recent searches

No recent searches.